Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.38 0.24 −1.22%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

Where the cash went Q3 FY2026, quarter to 30 September 2026

Free cash flow was −$24.4M: capital expenditures were more than operating cash flow. Cash fell by $1.5M. Lines the picture does not name came to −$386.2M. What is a cash flow statement?

Free cash flow
−$24.4M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$1.5M over the period
Where the cash went, in billions of dollars
Operating cash flow0.0
Free cash flow0.0
Shares issued, net+0.4
Other−0.4
Change in cash0.0
Operating cash flow, capex and free cash flow, three quartersOperating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, three quarters
Q1 FY26Q2 FY26Q3 FY26
Operating cash flow$0.0B$0.0B$0.0B
Capex$0.0B$0.0B$0.0B
Free cash flow$0.0B$0.0B$0.0B

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Net Income
(26.49) (14.99) (14.28) (6.45)

+3 more quarters

Depreciation & Amortization
0.00 0.00 0.00 —
Non Cash Items (Other)
8.44 1.09 1.76 —
Accounts Payable Change
0.13 (5.94) 6.88 —
Change in payables and accrued liability
3.20 3.01 0.91 —
Change in other assets and liabilities
(9.65) (0.12) (0.45) —
Operating Cash Flow
(24.37) (16.95) (5.19) (1.27)
Capital expenditures
0.00 0.01 (0.04) —
Other investing activities
0.00 0.00 (3.00) (0.83)
Investing cash flow
(382.45) 0.01 (3.04) (0.83)
Equity Repurchase (Preffered, Net)
(0.01) 59.96 (0.36) —
Other financial activities
(3.78) — — —
Financing cash flow
405.28 59.20 (0.36) 23.74
Change in Cash
(1.54) 42.26 (8.58) 21.63
Beginning Cash
0.00 0.00 89.16 —
Ending Cash
(1.54) 42.26 80.58 21.63
Stock Based Compensation
8.94 1.09 1.76 —
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(6.32) (3.05) 7.33 1.98
Issuance/Purchase of Shares
409.06 59.96 (0.36) 23.74

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 12 Nov 2026